BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical firm centered on creating novel artificial lethality-based most cancers therapeutics concentrating on DNA harm response (DDR) pathways, immediately introduced that the summary titled “ATRN-W1051, a novel and potent WEE1 inhibitor for the remedy of CCNE1-overexpressing ovarian most cancers” will probably be offered on the 14th Biennial Digital today techs Ovarian Most cancers Analysis Seminar Collection offered by the Rivkin Middle and the American Affiliation for Most cancers Analysis (AACR). The sequence will happen on September 21, 22, 28, and 29, 2022, with every day scheduled to run from 12:00-2:00pm U.S. Pacific Time.
“A rising physique of scientific proof offers thrilling improvement alternatives for our WEE1 inhibitor, ATRN-W1051,” mentioned Oren Gilad, Ph.D., President and Chief Govt Officer of Aprea. “ATRN-W1051 is designed to be a potent and selective WEE1 inhibitor with a differentiated construction and doubtlessly preferable pharmacokinetic properties. The offered knowledge show anti-proliferative exercise in opposition to a wide range of most cancers cell traces and tumor development inhibition in a genetically-defined ovarian most cancers xenograft mannequin. We sit up for finishing the IND-enabling research and plan to provoke the scientific program shortly thereafter.”
A duplicate of the poster will probably be accessible from the “Occasions Calendar” within the Information and Occasions part of the Aprea web today techs site.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical firm headquartered in Boston, Massachusetts with analysis services in Doylestown, Pennsylvania, centered on creating novel artificial lethality-based most cancers therapeutics concentrating on DNA today techs harm response pathways. The Firm’s lead program is ATRN-119, a Part 1-ready small molecule ATR inhibitor being developed for stable tumor indications. ATRN-W1051, the Firm’s novel WEE1 inhibitor, is in preclinical improvement. For extra info, please go to the corporate web site at www.aprea.com.
The Firm could use, and intends to make use of, its investor relations web site at https://ir.aprea.com/ as a way of exposing materials nonpublic info and for complying with its disclosure obligations beneath Regulation FD.
Ahead Wanting Statements
Sure info contained on this press launch contains “forward-looking statements”, throughout the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Change Act of 1934, as amended, associated to our scientific trials, regulatory submissions and strategic plans. We could, in some instances use phrases resembling “predicts,” “believes,” “potential,” “proceed,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “could,” “might,” “would possibly,” “seemingly,” “will,” “ought to” or different phrases that convey uncertainty of the long run occasions or outcomes to determine these forward-looking statements. The forward-looking statements are based mostly on present beliefs and expectations of our administration crew that contain dangers, potential adjustments in circumstances, assumptions, and uncertainties. Any or the entire forward-looking statements could become flawed or be affected by inaccurate assumptions our administration crew would possibly make or by identified or unknown dangers and uncertainties. These forward-looking statements are topic to dangers and uncertainties together with, with out limitation, dangers associated to the success and timing of our scientific trials or different research and the opposite dangers set forth in our filings with the U.S. Securities and Change Fee, together with our Annual Stories on Kind 10-Okay and Quarterly Stories on Kind 10-Q. Ahead-looking statements concerning our product candidates are additionally topic to extra dangers and uncertainties, together with with out limitation, with respect to: our dependence on extra financing to fund our operations and full the event and commercialization of our product candidates, and the dangers that elevating such extra capital could limit our operations or require us to relinquish rights to our applied sciences or product candidates; our restricted historical past and preclinical standing of the belongings we acquired from Atrin Prescribed drugs Inc.; our marketing strategy or the probability of the profitable implementation of such marketing strategy; the timing of initiation of deliberate scientific trials for our product candidates; the long run success of such trials; the profitable implementation of our analysis and improvement packages and collaborations and the interpretation of the outcomes and findings of such packages and collaborations and whether or not such outcomes are adequate to assist the long run success of our product candidates; the success, timing and value of our anticipated scientific trials for our present product candidates; the timing of initiation, futility analyses, knowledge presentation, reporting and publication and receipt of interim outcomes today techs (together with, with out limitation, any preclinical outcomes or knowledge); any statements about our understanding of product candidates mechanisms of motion and interpretation of preclinical and early scientific outcomes from its scientific improvement packages and any collaboration research; and different components, together with legislative, regulatory, political and financial developments not inside our management. For all these causes, precise outcomes and developments could possibly be materially totally different from these expressed in or implied by our forward-looking statements. You might be cautioned to not place undue reliance on these forward-looking statements, that are made solely as of the date of this press launch. We undertake no obligation to replace such forward-looking statements to replicate subsequent occasions or circumstances, besides to the extent required by regulation or regulation.
Supply: Aprea Therapeutics, Inc.
Scott M. Coiante
Sr. Vice President and Chief Monetary Officer
Gregory A. Korbel
Sr. Vice President and Chief Working Officer